Cardiac Malignant Peripheral Nerve Sheath Tumor Accessed By 18F-FDG PET/CT

Brandão, Simone Cristina Soares; Dompieri, Luca Terracini; Tonini, Romero Carlos; Grativvol, Petherson Susano; Gama, Juliano Dallapicula; Calado, Eveline Barros; Pedroti, Fátima Cristina Monteiro

doi:10.1016/j.cjca.2019.12.035

Cited by 2 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This test has no limitations with regard to acoustic window, metallic prostheses, and kidney failure. 8,[13][14][15][16] PET/CT uses radiopharmaceuticals to define images, such as fluorine-18 fluorodeoxyglucose ( 18 F-FDG). The uptake of this substance by tumor cells reflects their metabolic activity and level of disease aggressiveness, helping to differentiate between malignant and benign tumors and thus avoiding cardiac biopsies and unnecessary invasive treatments.…”

Section: Cauduro Et Al Obstructive Cardiac Tumorsmentioning

confidence: 99%

Obstructive Cardiac Tumors

Cauduro,

Dutra,

Fernandes

et al. 2022

ABC: Heart Failure &Amp; Cardiomyopathy

View full text Add to dashboard Cite

Cardiac tumors are considered rare clinical entities and can affect any cardiac tissue. Metastatic (secondary) cardiac tumors are more frequently diagnosed than primary tumors (malignant or benign). Both types can cause valve and/or inflow and outflow tract obstructions in any cardiac chamber, leading to symptoms of heart failure, as well as embolization and arrhythmia. Treatment of benign tumors is usually surgical, and that of metastatic and primary malignant tumors will depend on their origin and type, with poor prognosis. Recurrence of benign tumors is frequent. The aim of this article is to provide the clinician with tools to optimize diagnosis, differential diagnosis, and treatment of tumors with obstructive features causing heart failure.

show abstract

Section: Cauduro Et Al Obstructive Cardiac Tumorsmentioning

confidence: 99%

Obstructive Cardiac Tumors

Cauduro,

Dutra,

Fernandes

et al. 2022

ABC: Heart Failure &Amp; Cardiomyopathy

View full text Add to dashboard Cite

show abstract

Primary Cardiac Schwannoma: A Meta-Analysis of Individual Case Reports

Rahouma

Baudo

Khairallah

et al. 2023

JCM

View full text Add to dashboard Cite

Primary cardiac schwannoma (PCS) is a neurogenic tumor that arises from Schwann cells. Malignant schwannoma (MSh) is an aggressive cancer comprising 2% of all sarcomas. Information on the proper management of these tumors is limited. Four databases were searched for case reports/series of PCS. The primary outcome was overall survival (OS). Secondary outcomes included therapeutic strategies and the corresponding outcomes. Among 439 potentially eligible studies, 53 met the inclusion criteria. The patients included had 43.72 ± 17.76 years and 28.3% were males. Over 50% of patients had MSh, with 9.4% also demonstrating metastases. Schwannoma commonly occurs in the atria (66.0%). Left-sided PCS were more common than right-sided ones. Surgery was performed in almost 90% of the cases; chemotherapy and radiotherapy were used in 16.9% and 15.1% of cases, respectively. Compared to benign cases, MSh occurs at a younger age and is commonly located on the left side. OS of the entire cohort at 1 and 3 years were 60.7%, and 54.0%, respectively. Females and males OS were similar up to 2 years follow-up. Surgery was associated with higher OS (p < 0.01). Surgery is the primary treatment option for both benign and malignant cases and was the only factor associated with a relative improvement in survival.

show abstract

Cardiac Malignant Peripheral Nerve Sheath Tumor Accessed By 18F-FDG PET/CT

Cited by 2 publications

References 5 publications

Obstructive Cardiac Tumors

Obstructive Cardiac Tumors

Primary Cardiac Schwannoma: A Meta-Analysis of Individual Case Reports

Contact Info

Product

Resources

About